Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial …
The study population was derived from a DOAC-Taiwan (DOAC-T) cohort. Patients aged ≥ 20 years who used rivaroxaban, apixaban, or edoxaban for > 3 days …Read More
